- Report
- March 2024
- 195 Pages
Global
From €3258EUR$3,374USD£2,759GBP
€3620EUR$3,749USD£3,065GBP
- Report
- May 2024
- 391 Pages
Global
From €5317EUR$5,700USD£4,350GBP
- Report
- July 2023
- 70 Pages
Global
From €5745EUR$5,950USD£4,865GBP
- Report
- February 2024
- 250 Pages
Global
From €4828EUR$5,000USD£4,088GBP
- Report
- May 2024
- 193 Pages
Global
From €5407EUR$5,600USD£4,578GBP
- Report
- September 2023
- 76 Pages
Global
From €4779EUR$4,950USD£4,047GBP
- Report
- March 2024
- 145 Pages
Global
From €3764EUR$3,899USD£3,188GBP
- Report
- April 2024
- 180 Pages
Global
From €4731EUR$4,900USD£4,006GBP
- Report
- January 2024
- 250 Pages
Global
€4823EUR$4,995USD£4,084GBP
- Report
- March 2024
- 118 Pages
Global
From €4345EUR$4,500USD£3,679GBP
- Report
- June 2023
- 72 Pages
United States
From €1207EUR$1,250USD£1,022GBP
- Report
- October 2023
- 85 Pages
United States
From €4586EUR$4,750USD£3,883GBP
- Report
- August 2023
- 205 Pages
Europe
From €2028EUR$2,100USD£1,717GBP
€2897EUR$3,000USD£2,453GBP
- Report
- January 2024
- 138 Pages
Europe
From €3571EUR$3,699USD£3,024GBP
- Report
- February 2024
- 175 Pages
Global
From €4828EUR$5,000USD£4,088GBP
- Report
- February 2024
- 250 Pages
Global
From €4828EUR$5,000USD£4,088GBP
- Report
- January 2024
- 200 Pages
Global
From €4828EUR$5,000USD£4,088GBP
- Report
- February 2024
- 116 Pages
Global
From €4586EUR$4,750USD£3,883GBP
- Report
- June 2024
- 1130 Pages
Global
From €1222EUR$1,310USD£1,000GBP
- Report
- December 2023
- 76 Pages
Global
From €7719EUR$7,995USD£6,536GBP
The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more